High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection

Phase 2

Completed

• Conditions: Urinary Tract Infection
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: High Strength Cranberry

• Registration Number: NCT03042273
• Lead Sponsor: Swisse Wellness Pty Ltd

Brief Summary

This clinical trial is a Phase 2, multicenter, placebo-controlled, double-blind, parallel-arm study to evaluate the efficacy and safety of High Strength Cranberry (500mg Pacran®) in preventing UTI (cystitis) in women with a history of recurrent UTI (rUTI).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-02-01
• Study First Submitted QC: 2017-02-01
• Study First Posted: 2017-02-03
• Study Start: 2017-05-15
• Status Verified: 2019-06
• Primary Completion: 2019-12-31
• Study Completion: 2019-12-31
• Last Update Submitted: 2020-03-16
• Last Update Posted: 2020-03-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 150

Inclusion Criteria

1. Females aged 18-65 years, inclusive
2. A history of recurrent urinary tract infection defined as ≥3 UTIs in the last year OR at least 2 UTIs occurring in the last 6 months. Each infection requires confirmation by a health professional
3. Willing to answer questionnaires and comply with the study requirements
4. Ability to swallow capsules
5. Provided Written Informed Consent
6. BMI >17.5kg m2 and <35kg m2

Exclusion Criteria

1. Microbial growth on urine culture of ≥107 cfu/L (104cfu/mL) within 7 days of Day 1
2. A history of >5 UTIs in the last 6 months (confirmed by self-report or health professional)
3. Use of antibiotics or antibiotics for prophylaxis within 28 days of Day 1
4. Use of any antibacterial products, that in the opinion of the Medical Investigator may interfere with the study outcomes, within 28 days of Day 1
5. Regular use of Vaccinium containing products (e.g. all forms of blueberries, cranberries, bilberry, lingonberry , etc i.e fruit, dried fruit, pills, juices or supplements) within 28 days of Day 1 at the discretion of the Medical Investigator
6. Presence of an intermittent or indwelling urinary catheter
7. Anatomical abnormalities of the urinary tract
8. History of or known clinically significant renal or urological disease(self-reported)
9. Positive urine dipstick pregnancy test at screening onDay 1, currently pregnant and/or breastfeeding
10. Women of Childbearing potential not willing to use adequate and effective methods of contraception throughout the study
11. Women of child bearing potential that have not been using effective methods of contraception for 14 days prior to Day 1
12. History of or known clinically significant cardiac disease
13. History of or known clinically significant liver disease
14. History of or known clinically significant gastrointestinal disease
15. History of or known metabolic disorder or diabetes
16. History or presence of alcohol or illicit drug abuse,any surgical history, clinical condition or organ dysfunction that in the opinion of the Medical Investigator may affect the participant's ability to participate in the study or the study results
17. Currently hospitalised or any planned hospitalisations within 1 month following the last dose of study product
18. Immunocompromised participants or participants receiving immunosuppressive medication
19. History of an adverse reaction or known hypersensitivity or suspected allergy to the investigational product ingredients
20. Currently taking warfarin or has received Warfarin within 28 days of Day 1
21. Received an investigational drug within 28 days of Day 1

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	1 capsule of Matching Placebo orally daily for 6 months
High Strength Cranberry	High Strength Cranberry	1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months

Primary Outcome Measures

Name	Time	Method
Incidence of UTI	6 months	cultured confirmed UTIs at a level of \>108cfu/L (105cfu/mL)

Trial Locations

Locations (4)

Holdsworth House Medical Centre; 🇦🇺 Brisbane, Queensland, Australia

Griffith University Clinical Trial Unit (Griffith Health); 🇦🇺 Gold Coast, Queensland, Australia

Monash Alfred Psychiatry Research Centre (MAPrc); 🇦🇺 Melbourne, Victoria, Australia

CSIRO Nutrition and Health Research Clinic; 🇦🇺 Adelaide, South Australia, Australia